Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667507 | 1.00 | TSHR (0.35) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15591881 | 1.00 | TSHR (0.35) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29009039 | 1.00 | TSHR (0.35) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23303049 | 0.89 | LMNA (0.35) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15468776 | 0.88 | — | — | |
| SCHEMBL26626710 | 0.86 | LMNA (0.33) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29145410 | 0.82 | MGMT (0.35) | TSHRMGMTALDH1A1TP53HIF1A | |
| SCHEMBL29458085 | 0.82 | MGMT (0.35) | TSHRMGMTALDH1A1TP53HIF1A | |
| SCHEMBL28515735 | 0.82 | PRSS1 (0.35) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL22512052 | 0.81 | MGMT (0.34) | MGMTABCG2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773642-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | Afraxis Holdings, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| WO-2013067423-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | PAK2, PAK3, PAK1 | TSHR 3372/4885CHRM2 4876/4885CHRM4 4871/4885 |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | TSHR 1872/4885CHRM2 4867/4885CHRM4 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.